

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. DOX 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/028,172	12/21/2001	Yoichi Takahama	322732000401	2837
25225 7	590 06/09/2003		•	
MORRISON & FOERSTER LLP			EXAMINER .	
3811 VALLEY CENTRE DRIVE SUITE 500 SAN DIEGO, CA 92130-2332		LI, BAO Q		ro G
	CA 92130-2332	· .	ART UNIT	PAPER NUMBER
			1648	Λ
			DATE MAILED: 06/09/2003	
				4
				/ .

Please find below and/or attached an Office communication concerning this application or proceeding.

4,		<u></u>				
	Application No.	Applicant(s)				
Office Action Commence	10/028,172	TAKAHAMA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Bao Qun Li	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on 17 N	larch 2003 .					
2a) This action is <b>FINAL</b> . 2b) Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims						
4)⊠ Claim(s) 13-30 is/are pending in the application	n.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 13-30 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				
S. Patent and Trademark Office						

Application/Control Number: 10/028,172

Art Unit: 1648

, i

## **DETAILED ACTION**

Amendment in response to the previous Office Action on *Election/Restrictions* filed on 03/17/2003 has been acknowledged. Claims 1-12 have been canceled. New claims 13-30 have been added. Since the newly added claims are no longer read on the same invention as claims 1-12 as previous claimed, the previous Office Action *Election/Restrictions* mailed on 02/11/2003 is vacated. A new Office Action on *Election/Restrictions* is follows:

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 13-17, 19-20, 23-30, drawn to a diagnosis reagent comprising an recombinant antigen and a single synthetic antigen of HCV antigen, classified in class 424, subclass 228.
  - II. Claims 13-15, 18, 21-22, 24-30, drawn to a diagnostic reagent comprising an recombinant HCV antigen and three synthetic HCV antigens, classified in class 424, subclass 202.1.

Upon election of Group I, Applicant is additionally required to elect a single synthetic HCV antigen from: A). HCV core antigen, B). HCV NS4 antigen and C). HCV NS5 antigen to be examined on the merits. This requirement is not to be construed as a requirement for an election of species, since each of the antigen is not a member of a single genus of invention, but constitute an <u>independent and patentably distinct invention</u>.

The reason the election/restriction follows:

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions Groups I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of groups I and II are directed to the structurally and functionally different products, e.g. product of Group I comprises one recombinant antigen and one synthetic antigen, whereas the product of Group II comprises one recombinant antigen and more than three synthetic antigens. They produce different effects.
- 3. Inventions Groups A, B and C are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation,

Application/Control Number: 10/028,172

Art Unit: 1648

different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of groups A-C are directed to structurally and functionally different antigens, e.g. the antigen of the group A is core antigen, whereas the antigen of group B is a NS4 antigen.

- Because these inventions are distinct for the reasons given above and the search required 4. for Group I is not required for Group II or search for group A does not need to search group B, restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- Applicant is reminded that upon the cancellation of claims to a non-elected invention, the 6. inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 703-305-1695. The examiner can normally be reached on 7:00 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Bao Qun Li

Cooque N

June 6, 2003